Cite

HARVARD Citation

    De Carlo, E. et al. (2021). Brigatinib as a treatment of ALK-positive non-small cell lung cancer. Expert review of precision medicine and drug development. 6 (5), pp. 299-305. [Online]. 
  
Back to record